KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EPS (Basic) (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed EPS (Basic) for 18 consecutive years, with -$0.56 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) rose 39.78% year-over-year to -$0.56; the TTM value through Mar 2026 reached -$1.99, up 33.44%, while the annual FY2025 figure was -$2.38, 21.71% up from the prior year.
  • EPS (Basic) hit -$0.56 in Q1 2026 for Ionis Pharmaceuticals, up from -$1.41 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.78 in Q2 2025 and bottomed at -$1.41 in Q4 2025.
  • Average EPS (Basic) over 5 years is -$0.61, with a median of -$0.66 recorded in 2024.
  • Year-over-year, EPS (Basic) tumbled 1000.0% in 2024 and then soared 273.33% in 2025.
  • Ionis Pharmaceuticals' EPS (Basic) stood at -$0.37 in 2022, then skyrocketed by 83.78% to -$0.06 in 2023, then crashed by 1000.0% to -$0.66 in 2024, then tumbled by 113.64% to -$1.41 in 2025, then soared by 60.28% to -$0.56 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.56, -$1.41, and -$0.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.